NETRIS Pharma Secures €7.25 Million in Horizon Europe Funding to Advance Phase 2b Clinical Trial in Head and Neck Cancer
LYON FRANCE AND GENEVA , SWITZERLAND, May 28, 2026 /EINPresswire.com/ -- NETRIS Pharma, a clinical-stage oncology company targeting the netrin-1 / epithelial-to-mesenchymal transition (EMT) axis, today announced that it has secured €7.25 …